In this issue:
US lung cancer screening recommendations
Cisplatin + nab-paclitaxel with thoracic radiotherapy for locally advanced NSCLC
Metformin use and lung cancer survival
MPE recurrence in metastatic EGFR-/ALK-mutated NSCLC
Brigatinib for ALK-positive NSCLC previously treated with TKIs
Gene mutation signature for predicting immunotherapy benefits in NSCLC
Carboplatin + nab-paclitaxel vs. cisplatin + gemcitabine for chemotherapy-naïve SCC
Second- or later-line anti-PD-1/L1 + anti-angiogenesis therapy in advanced lung adenocarcinoma
Patterns of recurrence of pN2 NSCLC
Pathological nodal disease and survival in lung cancer with MPR after neoadjuvant chemotherapy
Please login below to download this issue (PDF)